Product image of Metformina + Sitagliptina Farmoz (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metformina + Sitagliptina Farmoz

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metformina + Sitagliptina Farmoz (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metformina + Sitagliptina Farmoz, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. The combination leverages complementary mechanisms to lower hepatic glucose output and enhance insulin secretion. They treat type 2 diabetes mellitus in adult patients by improving blood glucose control.

GNH India supplies Metformina + Sitagliptina Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing high‑quality generic medicines that meet European Union standards.

Manufacturer / TM Owner

Farmoz - Sociedade Técnico Medicinal, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Sitagliptina Farmoz is used in the management of type 2 diabetes mellitus, targeting glucose regulation.

  • Type 2 diabetes mellitus: improves overall glycemic control when added to diet, exercise and existing therapy.
  • Inadequate control on metformin alone: provides additional glucose‑lowering effect as adjunct therapy.
  • Inadequate control on sitagliptin alone: offers combined action to enhance insulin secretion and reduce hepatic glucose production.

How It Works

  • Metformin Hydrochloride reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby decreasing fasting glucose levels. Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP). The elevated incretins stimulate glucose‑dependent insulin release and suppress glucagon secretion, resulting in lower post‑prandial glucose. Together, the agents provide complementary actions on both fasting and post‑prandial glucose pathways.

Side Effects

Metformina + Sitagliptina Farmoz may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: loose stools, often transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild tension‑type headache.
  • Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic condition.
  • Severe hypoglycemia: especially when combined with other glucose‑lowering agents.
  • Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
  • Hepatotoxicity: liver enzyme elevations or injury.
  • Allergic reactions: rash, itching, or angioedema.

Precautions & Warnings

Before prescribing Metformina + Sitagliptina Farmoz, clinicians should consider several safety considerations.

  • Renal function: assess creatinine clearance; dose adjustment may be needed in impairment.
  • Hepatic disease: use cautiously in patients with liver dysfunction.
  • Cardiovascular status: monitor for heart failure, especially with metformin.
  • Risk of hypoglycemia: educate patients when used with insulin or sulfonylureas.
  • Pregnancy and lactation: avoid unless benefits outweigh risks; consult guidelines.
  • Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Avoid Interactions

Metformina + Sitagliptina Farmoz can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; withhold metformin before and after imaging.
  • Strong CYP3A4 inhibitors: increase sitagliptin plasma levels, raising risk of adverse effects.
  • Insulin or sulfonylureas: potentiate hypoglycemia; dose adjustments required.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin.
  • ACE inhibitors/ARBs: combined use may impact renal function.
  • Corticosteroids: can raise blood glucose, reducing drug effectiveness.
  • Alcohol: can increase risk of lactic acidosis with metformin.

Frequently Asked Questions

Metformina + Sitagliptina Farmoz is an oral antidiabetic medication indicated for the treatment of type 2 diabetes mellitus in adults. It is used to improve glycaemic control when diet, exercise, and other therapies are insufficient.

Metformin lowers hepatic glucose production and increases insulin sensitivity, while Sitagliptin blocks the DPP‑4 enzyme, prolonging the action of incretin hormones that stimulate insulin release and suppress glucagon. The combined effect targets both fasting and post‑prandial blood glucose.

The dose is individualized by the prescribing healthcare professional based on the patient’s renal function, glycaemic targets, and concomitant therapies. No fixed regimen is provided here; the prescriber sets the appropriate dosage.

Safety in pregnancy and lactation has not been established. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should follow current clinical guidelines.

Enquiries can be submitted on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy, the metformin‑sitagliptin combo offers complementary mechanisms that can achieve better glycaemic control without the weight gain often seen with sulfonylureas or insulin. It is generally well tolerated and provides a convenient single‑tablet regimen.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging. Keep them away from moisture and direct sunlight to maintain stability.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the timing without medical advice.

The most serious adverse events include lactic acidosis (related to metformin) and severe hypoglycaemia when combined with other glucose‑lowering agents. Pancreatitis and rare allergic reactions are also reported and require immediate medical attention.

Patients with severe renal impairment, known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with uncontrolled heart failure or severe hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT